Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Caladrius opens phase IIb trial of CLBS-16 for coronary microvascular dysfunction

Jan. 20, 2021

LCP2 is a therapeutic target in lethal sepsis

Jan. 19, 2021

Apabetalone protects from heart failure in patients with T2D and ACS

Jan. 13, 2021

Nanjing Greepharma patents new ARG1 inhibitors

Jan. 12, 2021

Bristol Myers Squibb discloses new FPR2 agonists

Jan. 11, 2021

Novartis presents new NPR1-targeting antibodies

Jan. 5, 2021

Novel urotensin II receptor antagonists show efficacy in a mouse pressor response model

Jan. 4, 2021

BIAL-Portela & Ca. discovers dopamine beta-monooxygenase inhibitors

Dec. 30, 2020

Novel lipid conjugates of APJ agonist peptides show prolonged half-life for once-daily dosing

Dec. 30, 2020

Discovery and preclinical evaluation of a new sGC stimulator for hypertension treatment

Dec. 18, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...